



IFW

Docket No. 73933/5193

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Jean E. F. Rivier et al.

Application No.: 10/763,935

Filed: January 22, 2004

Title: CRFR1 SELECTIVE
LIGANDS

Group Art Unit: 1646

Examiner: TBD

) I hereby certify that this correspondence is
) being deposited with the United States
) Postal Service with sufficient postage as
) first class mail in an envelope addressed to:

) Mail Stop: Amendment

) Commissioner for Patents

) P.O. Box 1450

) Alexandria, VA 22313-1450

) on this date:

) 05/26/2004

Karin E. Harden
Karin E. Harden

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

This Information Disclosure Statement is submitted:

 X Under 37 CFR §1.97(b) (within three months of the filing date of a national application or date of entry of an international application, or before the mailing date of a first Office Action on the merits, whichever occurs last). However, should a first Office Action on the merits be mailed unbeknownst to the undersigned prior to the date of mailing of this paper, the fee requested under §1.17(p) may be charged to Deposit Account No. 06-1135.

 Under 37 CFR §1.97(c) together with either:
 a statement under 37 CFR §1.97(e), or
 a fee under 37 CFR §1.17(p)
 (after the 37 CFR §1.97(b) time period, but before the mailing date of a final Action, a Notice of Allowance, or an action that otherwise closes prosecution).

IDS

Application No. 10/763,935

Page 2


- ____ Under 37 CFR §1.97(d) together with:
- ____ a statement under 37 CFR §1.97(e), and
 - ____ a fee under 37 CFR §1.17(p)
(after the 37 CFR §1.97(c) time period, but on or before payment of the issue fee).

In accordance with the duty of disclosure imposed by 37 CFR § 1.56 to inform the Patent Office of all patents, publications, applications and other information known by Applicants or Applicants' representative that may be material to the examination of the subject application, Applicants' representative hereby provides this Information Disclosure Statement that is prepared in accordance with 37 CFR §§ 1.97-1.98 and includes Form PTO-1449 with _____ () references listed as items AA-__.

It is requested that the information provided herein be made of record in this application.


Dated: May 26, 2004

Respectfully submitted,



James J. Schumann
Attorney for Applicant(s)
Reg. No. 20, 856

Address all Correspondence to:
FITCH, EVEN, TABIN & FLANNERY
120 So. LaSalle Street
Suite 1600
Chicago, IL 60603
(858) 552-1311



Form PTO-1449 (Modified) INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Application No.	10/763,935
	Filing Date	January 22, 2004
	First Named Inventor	Jean E. F. Rivier et al.
	Group Art Unit	1646
	Examiner Name	TBD
Sheet 1 of 1	Attorney Docket No.	73933/5193

U.S. PATENT DOCUMENTS									
EXAMINER INITIALS*	CITE NO.	COPY NOT ENCLOSED PER 37 CFR § 1.98(d)	U.S. PATENT DOCUMENT		NAME OF INVENTOR OR APPLICANT	DATE OF ISSUANCE OR PUBLICATION (MM-DD- YYYY)	CLASS	SUB CLASS	FILING DATE
			PATENT, PUB., OR APP. NO.	KIND CODE (if known)					
	AA								

FOREIGN PATENT DOCUMENTS										
EXAMINER INITIALS*	CITE NO.	COPY NOT ENCLOSED PER 37 CFR § 1.98(d)	FOREIGN PATENT DOCUMENT			DATE OF PUBLICATION (MM-DD-YYYY)	CLASS	SUB CLASS	TRANSLATION	
			COUNTRY OR OFFICE (two-letter code)	DOCUMENT NO.	KIND CODE (if known)				YES	NO

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS			
EXAMINER INITIALS*	CITE NO.	COPY NOT ENCLOSED PER 37 CFR § 1.98(d)	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	CA		LAWRENCE, A.J. et al., "The highly selective CRF ₂ receptor antagonist K41498 binds to presynaptic CRF ₂ receptors in rat brain", <u>British Journal of Pharmacology</u> , 2002, pps. 896-904, Vol. 136, No. 6, GB
	CB		BONK, INES et al., "Development of a selective photactivatable antagonist for corticotropin-releasing factor receptor, type 2 (CRF ₂)", <u>Eur. J. Biochem.</u> , 2002, pps. 5288-5294, Vol. 269
	CC		RÜHMANN, ANDREAS et al., "Structural requirements for peptidic antagonists of the corticotropin-releasing factor receptor (CRFR): Development of CRFR2β-selective antisauvagine-30", <u>Proc. Natl. Acad. Sci.</u> , December 1998, pps. 15264-15269, Vol. 95, USA
Examiner Signature			Date Considered
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP §609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.			